Literature DB >> 32414883

Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.

Abdel Aziz Shaheen1, Kiarash Riazi2, Alexandra Medellin2, Deepak Bhayana2, Gilaad G Kaplan2, Jason Jiang2, Roy Park2, Wendy Schaufert2, Kelly W Burak2, Monica Sargious2, Mark G Swain2.   

Abstract

BACKGROUND: Identification of patients with nonalcoholic fatty liver disease (NAFLD) with advanced liver fibrosis in primary care remains an unmet need. Our primary objective was to implement a pathway driven by shear wave elastography (SWE) to facilitate risk stratification of patients with NAFLD within primary care and evaluate whether SWE assessment can reduce referrals of patients with NAFLD at low risk for fibrosis to hepatology.
METHODS: A multidisciplinary NAFLD clinical care pathway was codeveloped by hepatologists, radiologists and primary care physicians in Calgary to provide access to SWE-based screening of patients with NAFLD risk factors in primary care. The study outcome measures were estimated NAFLD-related referrals to the hepatology service in Calgary after implementation of the NAFLD pathway and characteristics of patients with NAFLD at risk for advanced fibrosis. The NAFLD pathway was implemented in January 2018 and was made available to all primary care physicians in the Calgary Health Zone. Patients with NAFLD who had liver stiffness (SWE value ≥ 8.0 kPa) or an inconclusive assessment were referred to hepatology. A serum liver fibrosis score was also measured with the fibrosis-4 (FIB-4) index, and performance of an FIB-4 index score of 1.30 or greater to risk stratify patients with NAFLD was evaluated. Demographic, clinical and laboratory characteristics of study groups were compared.
RESULTS: Between March and October 2018, 2084 patients with suspected NAFLD were evaluated. Nonalcoholic fatty liver disease was confirmed by ultrasonography in 1958 (94.1%). A majority of the cohort had elevated liver enzyme values (1028 [52.5%]) and obesity (body mass index ≥ 30) (1063/1764 [60.3%]). Most patients with NAFLD (1791 [91.5%]) had an SWE value less than 8.0 kPa and were not referred to hepatology. Sixty-seven patients (3.4%) had an SWE value of 8.0 kPa or more, and 100 (5.1%) had an inconclusive SWE; these patients were referred to hepatology. Using an FIB-4 index score cut-off of 1.30 would have led to hepatology referral of 396/1251 patients (31.6%).
INTERPRETATION: Implementation of a primary care-accessible SWE pathway for patients with NAFLD facilitated fibrosis risk stratification and greatly reduced hepatology referrals. Using the FIB-4 index score alone would led to higher rates of referral of patients with NAFLD. Copyright 2020, Joule Inc. or its licensors.

Entities:  

Year:  2020        PMID: 32414883      PMCID: PMC7239637          DOI: 10.9778/cmajo.20200009

Source DB:  PubMed          Journal:  CMAJ Open        ISSN: 2291-0026


  32 in total

1.  Squire 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process.

Authors:  Greg Ogrinc; Louise Davies; Daisy Goodman; Paul Batalden; Frank Davidoff; David Stevens
Journal:  Am J Crit Care       Date:  2015-11       Impact factor: 2.228

Review 2.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.

Authors:  G Musso; M Cassader; F Rosina; R Gambino
Journal:  Diabetologia       Date:  2012-01-27       Impact factor: 10.122

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

4.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

5.  Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.

Authors:  Salvatore Petta; Vito Di Marco; Rosaria Maria Pipitone; Stefania Grimaudo; Carola Buscemi; Antonio Craxì; Silvio Buscemi
Journal:  Liver Int       Date:  2018-05-07       Impact factor: 5.828

Review 6.  Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.

Authors:  Guangqin Xiao; Sixian Zhu; Xiao Xiao; Lunan Yan; Jiayin Yang; Gang Wu
Journal:  Hepatology       Date:  2017-09-26       Impact factor: 17.425

7.  Supersonic Shear Imaging and Transient Elastography With the XL Probe Accurately Detect Fibrosis in Overweight or Obese Patients With Chronic Liver Disease.

Authors:  Masato Yoneda; Emmanuel Thomas; Seth N Sclair; Tiffannia T Grant; Eugene R Schiff
Journal:  Clin Gastroenterol Hepatol       Date:  2015-03-21       Impact factor: 11.382

8.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.

Authors:  Zobair M Younossi; Deirdre Blissett; Robert Blissett; Linda Henry; Maria Stepanova; Youssef Younossi; Andrei Racila; Sharon Hunt; Rachel Beckerman
Journal:  Hepatology       Date:  2016-09-26       Impact factor: 17.425

9.  High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study.

Authors:  Llorenç Caballería; Guillem Pera; Ingrid Arteaga; Lluís Rodríguez; Alba Alumà; Rosa Ma Morillas; Napoleón de la Ossa; Alba Díaz; Carmen Expósito; Dolores Miranda; Carmen Sánchez; Rosa Ma Prats; Marta Urquizu; Angels Salgado; Magda Alemany; Alba Martinez; Irfan Majeed; Núria Fabrellas; Isabel Graupera; Ramón Planas; Isabel Ojanguren; Miquel Serra; Pere Torán; Juan Caballería; Pere Ginès
Journal:  Clin Gastroenterol Hepatol       Date:  2018-02-13       Impact factor: 11.382

Review 10.  Ultrasound Elastography: Review of Techniques and Clinical Applications.

Authors:  Rosa M S Sigrist; Joy Liau; Ahmed El Kaffas; Maria Cristina Chammas; Juergen K Willmann
Journal:  Theranostics       Date:  2017-03-07       Impact factor: 11.556

View more
  5 in total

Review 1.  Defining comprehensive models of care for NAFLD.

Authors:  Manuel Romero-Gómez; Jörn M Schattenberg; Jeffrey V Lazarus; Quentin M Anstee; Hannes Hagström; Kenneth Cusi; Helena Cortez-Pinto; Henry E Mark; Michael Roden; Emmanuel A Tsochatzis; Vincent Wai-Sun Wong; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-06-25       Impact factor: 46.802

Review 2.  Advancing the global public health agenda for NAFLD: a consensus statement.

Authors:  Jeffrey V Lazarus; Henry E Mark; Quentin M Anstee; Juan Pablo Arab; Rachel L Batterham; Laurent Castera; Helena Cortez-Pinto; Javier Crespo; Kenneth Cusi; M Ashworth Dirac; Sven Francque; Jacob George; Hannes Hagström; Terry T-K Huang; Mona H Ismail; Achim Kautz; Shiv Kumar Sarin; Rohit Loomba; Veronica Miller; Philip N Newsome; Michael Ninburg; Ponsiano Ocama; Vlad Ratziu; Mary Rinella; Diana Romero; Manuel Romero-Gómez; Jörn M Schattenberg; Emmanuel A Tsochatzis; Luca Valenti; Vincent Wai-Sun Wong; Yusuf Yilmaz; Zobair M Younossi; Shira Zelber-Sagi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-10-27       Impact factor: 46.802

3.  Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH).

Authors:  Giada Sebastiani; Keyur Patel; Vlad Ratziu; Jordan J Feld; Brent A Neuschwander-Tetri; Massimo Pinzani; Salvatore Petta; Annalisa Berzigotti; Peter Metrakos; Naglaa Shoukry; Elizabeth M Brunt; An Tang; Jeremy F Cobbold; Jean-Marie Ekoe; Karen Seto; Peter Ghali; Stéphanie Chevalier; Quentin M Anstee; Heather Watson; Harpreet Bajaj; James Stone; Mark G Swain; Alnoor Ramji
Journal:  Can Liver J       Date:  2022-02-04

Review 4.  Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting.

Authors:  Joana Vieira Barbosa; Michelle Lai
Journal:  Hepatol Commun       Date:  2020-10-31

5.  Two-Tier Care Pathways for Liver Fibrosis Associated to Non-Alcoholic Fatty Liver Disease in HIV Mono-Infected Patients.

Authors:  Giada Sebastiani; Jovana Milic; Adriana Cervo; Sahar Saeed; Thomas Krahn; Dana Kablawi; Al Shaima Al Hinai; Bertrand Lebouché; Philip Wong; Marc Deschenes; Claudia Gioè; Antonio Cascio; Giovanni Mazzola; Giovanni Guaraldi
Journal:  J Pers Med       Date:  2022-02-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.